Home
NewsNewsFertilAI has received EU MDR clearance for tools advancing Predictive AI in Fertility through its Fertilane platform. StimAI and OvuPredict help clinicians optimise IVF timing, predict ovulation and improve scheduling efficiency. The technology supports scalable fertility care, reduced monitoring needs and better patient treatment experiences globally.
FertilAI announced on April 15, 2026, that it has received CE marking under the EU Medical Device Regulation (EU MDR) for its clinical decision-support tools. The clearance applies to StimAI and OvuPredict, which are integrated into the company’s Fertilane platform to assist physicians with clinical timing during active treatment cycles. This development introduces a regulated application of Predictive AI in Fertility specifically designed to predict mature oocyte yields and natural cycle ovulation. StimAI, an EU MDR Class IIa device, forecasts the number of mature oocytes retrieved across different trigger timings to support IVF outcomes and laboratory workload management. OvuPredict, classified as EU MDR Class I, predicts ovulation up to six days in advance to assist in timing intrauterine insemination (IUI) and frozen embryo transfers (FET).
The Fertilane system is a SaaS solution that integrates with existing electronic medical record (EMR) systems. Its algorithms were developed using data from more than 100,000 cycles to support individualized care and operational scheduling. By utilizing Predictive AI in Fertility, the platform aims to reduce patient monitoring requirements and balance daily clinic workloads without affecting clinical outcomes. The technology is intended to provide data-driven insights during active treatment cycles, allowing for more predictable daily scheduling in both medical and laboratory environments.
Fertilane delivers two fertility-tailored algorithms:
FertilAI CEO Rohi Hourvitz stated that the EU MDR validation confirms the technology’s role in streamlining clinic operations and increasing service access without raising overhead. The advancement of Predictive AI in Fertility is positioned to address physician shortages and rising infertility rates. Hourvitz commented, "Our goal is to accelerate and ease the patients' fertility treatment journey to parenthood, no matter the path taken". He added, "With the global rise in infertility and a worldwide shortage of physicians driving higher costs and longer wait times, expanding access to care is absolutely vital. Having a system that enables clinic scalability while actively improving clinical benefits and the patient experience is a pivotal step forward in addressing this growing challenge".
Legacy, North America's leading digital male fertility clinic, has secured New York State CLEP approval for both its semen analysis and DNA fragmentation test – the only mandatory pre-market laboratory review programme in the United States. The approvals confirm clinical-grade validity for at-home samples, extending access to New York patients without a clinic visit.
From 1 July 2026, South Australia's Fertility Treatment Rebate Scheme provides eligible residents with a $250 rebate for pre-treatment testing and a $2,000 rebate for up to two fertility treatment cycles. Backed by an $18.5 million, four-year government commitment, the scheme directly addresses the financial barriers preventing South Australians from accessing fertility care.
apyen, a global leader in male fertility diagnostics, has entered a strategic partnership with My Surrogacy Journey to broaden fertility testing and reproductive health support for intended parents across the United States. The collaboration covers semen analysis, DNA fragmentation testing, and infectious disease screening, with plans for international expansion.
Nucleus Genomics has announced that the Fertility Institute of Hawaii Joins Nucleus IVF+ network, bringing advanced carrier and embryo screening to Hawaii's largest IVF practice. The partnership expands genetic optimization access across the Pacific, with risk reduction data covering endometriosis, heart disease, breast cancer, type 1 diabetes, and Alzheimer's disease.
TFC Taipei Fertility Center has introduced an AI-Powered Embryo Selection model that improves chromosomally normal embryo identification by up to 24%. Presented at ASPIRE 2026, the iDAScore v2.0 system brings precision and objectivity to IVF treatment, reducing implantation failure risk and shortening time to conception for infertile patients.
CDT Equity Inc. (Nasdaq: CDT) has announced the Canadian patent grant for AZD5904 in male infertility, completing approval across all key pharmaceutical target markets. The milestone strengthens CDT's IP position for the AstraZeneca-licensed Myeloperoxidase inhibitor as the company advances active out-licensing and strategic partnering discussions for the asset.
Nucleus Genomics has announced that Nucleus IVF+ joins SCRC, the Southern California Reproductive Center, as part of its rapidly expanding global network. The partnership integrates advanced carrier screening and embryo analysis across SCRC's four California locations, serving thousands of patients annually across Beverly Hills, Santa Barbara, Pasadena, and Ventura.
